GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?

Annales d'Endocrinologie

Volumn 74, Issue 5-6, 2013, Pages 515-522

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; LIXUMIA; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ARTICLE; BODY WEIGHT; CLINICAL DECISION MAKING; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG ELIMINATION; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EDEMA; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT PLANNING; VOMITING; WEIGHT GAIN;

CHOICE BEHAVIOR; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, GLUCAGON;

EID: 84889088792     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.06.002     Document Type: Article

References (64)

1. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
2. Tahrani A.A., Bailey C.J., Del Prato S., Barnett A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378:182-197.
3. Mudaliar S., Henry R.R. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia 2012, 55:1865-1868.
4. Nauck M.A., Vardarli I., Deacon C.F., Holst J.J., Meier J.J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 2011, 54:10-18.
5. Scheen A.J., Radermecker R.P., Philips J.C., Paquot N. Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse 2007, 3:1884. [p.86-8].
6. Scheen A.J. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 2012, 23:126-131.
7. Madsbad S. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med 2012, 23:132-136.
8. Davidson J.A. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010, 85:S27-S37.
9. Gallwitz B. GLP-1 agonists and dipeptidyl peptidase IV inhibitors. Handb Exp Pharmacol 2011, 203:53-74.
10. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
11. Gallwitz B. Anorexigenic effects of GLP-1 and its analogues. Handb Exp Pharmacol 2012, 209:185-207.
12. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215.
13. Cariou B. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes. Diabetes Metab 2012, 38:298-308.
14. Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011, 71:1675-1688.
15. Shyangdan D.S., Royle P., Clar C., Sharma P., Waugh N., Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, CD006423. [Published on line 2011/10/07]. 10.1002/14651858.CD006423.pub2.
16. Karagiannis T., Paschos P., Paletas K., Matthews D.R., Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012, 344:e1369.
17. ®). Incrétinomimétique indiqué dans le traitement du diabète de type 2 apres échec et en complément des antidiabétiques oraux. Rev Med Liege 2008, 63:158-165.
18. Nikfar S., Abdollahi M., Salari P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. J Pharm Pharm Sci 2012, 15:1-30.
19. ®): analogue du glucagon-like-peptide-1humain en une injection par jour pour le traitement du diabète de type 2. Rev Med Liege 2010, 65:464-470.
20. Perry C.M. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs 2011, 71:2347-2373.
21. Blonde L., Montanya E. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes Obes Metab 2012, 14(Suppl.2):20-32.
22. Christensen M., Knop F.K., Vilsboll T., Holst J.J. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011, 20:549-557.
23. Scheen A.J. Exenatide once weekly in type 2 diabetes. Lancet 2008, 372:1197-1198.
24. Murphy C.E. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2012, 46:812-821.
25. Pinelli N.R., Hurren K.M. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011, 45:850-860.
26. Barnett A.H. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab 2012, 14:304-314.
27. Monami M., Dicembrini I., Marchionni N., Rotella C.M., Mannucci E. Effects of glucagon-like Peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012, 2012:672658.
28. Vilsboll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771.
29. Verges B., Bonnard C., Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 2011, 37:477-488.
30. Monami M., Cremasco F., Lamanna C., Colombi C., Desideri C.M., Iacomelli I., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:215764.
31. Elashoff M., Matveyenko A.V., Gier B., Elashoff R., Butler P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141:150-156.
32. Dore D.D., Bloomgren G.L., Wenten M., Hoffman C., Clifford C.R., Quinn S.G., et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011, 13:559-566.
33. Drucker D.J., Sherman S.I., Bergenstal R.M., Buse J.B. The safety of incretin-based therapies: review of the scientific evidence. J Clin Endocrinol Metab 2011, 96:2027-2031.
34. Aroda V.R., Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011, 27:528-542.
35. Hurren K.M., Pinelli N.R. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother 2012, 46:710-717.
36. Scheen A.J. A review of gliptins in 2011. Expert Opin Pharmacother 2012, 13:81-99.
37. Monami M., Lamanna C., Desideri C.M., Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012, 29:14-25.
38. Monami M., Dicembrini I., Martelli D., Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011, 27(Suppl.3):57-64.
39. Goossen K., Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012, [Published on line 2012/04/24]. 10.1111/j.1463-1326.2012.01610.x.
40. Monami M., Dicembrini I., Antenore A., Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011, 34:2474-2476.
41. Willemen M.J., Mantel-Teeuwisse A.K., Straus S.M., Meyboom R.H., Egberts T.C., Leufkens H.G. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011, 34:369-374.
42. Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med 2011, 123:189-201.
43. Engel S.S., Williams-Herman D.E., Golm G.T., Clay R.J., Machotka S.V., Kaufman K.D., et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010, 64:984-990.
44. Scheen A.J. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010, 49:573-588.
45. Scheen A.J. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010, 12:648-658.
46. Scheen A.J. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Exp Opin Drug Metab Toxicol 2011, 7:1561-1576.
47. Scheen A.J., Radermecker R.P. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010, 375:1410-1412.
48. Deacon C.F., Mannucci E., Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes: a review and meta-analysis. Diabetes Obes Metab 2012, 14:762-767.
49. Aroda V.R., Henry R.R., Han J., Huang W., Deyoung M.B., Darsow T., et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012, 34:1247-1258.
50. Scheen A.J. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012, 38:89-101.
51. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
52. Bergenstal R.M., Wysham C., Macconell L., Malloy J., Walsh B., Yan P., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
53. Wysham C., Bergenstal R., Malloy J., Yan P., Walsh B., Malone J., et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once weekly exenatide. Diabet Med 2011, 28:705-714.
54. Russell-Jones D., Cuddihy R.M., Hanefeld M., Kumar A., Gonzalez J.G., Chan M., et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012, 35:252-258.
55. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
56. Pratley R., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011, 65:397-407.
57. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
58. Schernthaner G., Barnett A.H., Betteridge D.J., Carmena R., Ceriello A., Charbonnel B., et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010, 53:1258-1269.
59. Rodbard H.W., Jellinger P.S., Davidson J.A., Einhorn D., Garber A.J., Grunberger G., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
60. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
61. Scheen A.J. Controversy about the relative efficacy of DPP-4 inhibitors. Diabetologia 2012, 55:2848-2849.
62. International Diabetes Federation. Treatment algorithm for people with type 2 diabetes. 2012. http://wwwidforg/treatment-algorithm-people-type-2-diabetes%3Flanguage=fr.
63. Paolisso G., Monami M., Marfella R., Rizzo M.R., Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?. Adv Ther 2012, 29:218-233.
64. Van Gaal L.F., Gutkin S.W., Nauck M.A. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. Eur J Endocrinol 2008, 158:773-784.